Hemocompatibility of gallium-68 labeled iron oxide nanoparticles coated with 2,3-dicarboxypropane-1,1-diphosphonic acid.
(68)Ga-DPD-Fe(3)O(4) contrast agent
Dual-modality contrast agents
Hemocompatibility with red blood cells
Red blood cells membrane deconstructions
Journal
Materials science & engineering. C, Materials for biological applications
ISSN: 1873-0191
Titre abrégé: Mater Sci Eng C Mater Biol Appl
Pays: Netherlands
ID NLM: 101484109
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
28
01
2020
revised:
13
05
2020
accepted:
24
05
2020
entrez:
1
7
2020
pubmed:
1
7
2020
medline:
30
3
2021
Statut:
ppublish
Résumé
Dual-modality contrast agents (DMCA), such as radiolabeled magnetic nanoparticles, have attracted significant attention in diagnostic applications due to their potency for the timely and accurate diagnosis of diseases. The hemocompatibility of a candidate DMCA with human blood is essential for the investigation of its application in vivo. In this respect, here we focused on the evaluation of the hemocompatibility of a new DMCA, that is based on iron oxide nanoparticles (i.e. Fe
Identifiants
pubmed: 32600720
pii: S0928-4931(20)30393-3
doi: 10.1016/j.msec.2020.111121
pii:
doi:
Substances chimiques
Diphosphonates
0
Gallium Radioisotopes
0
Gallium-68
98B30EPP5S
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
111121Informations de copyright
Copyright © 2020. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.